Ampersand Capital Partners Invests in Magritek

Ampersand Capital Partners Acquires Specac Ltd.

March 13, 2024

Manufacturing

Ampersand Capital Partners, a Boston-based private equity firm focused on healthcare and life sciences, has acquired Specac Ltd., a UK-based designer and manufacturer of FTIR spectroscopy accessories and sample preparation solutions. The acquisition will support Specac's growth trajectory and leverage Ampersand's experience in life-sciences-oriented lab products and OEM channels.

Ampersand Capital Partners Invests in Sterling Medical Devices

June 23, 2022

Medical Devices

Ampersand Capital Partners, a healthcare-focused private equity firm, made a growth equity investment in Sterling Medical Devices, a Moonachie, New Jersey-based provider of design, development and regulatory services for the medical device industry. The investment is intended to support Sterling’s continued growth and capability expansion across product development, software/electromechanical integration, and regulatory affairs.

Ampersand Capital Partners Invests in Syft Technologies

April 18, 2022

Manufacturing

Ampersand Capital Partners made a minority growth equity investment in Syft Technologies Limited to accelerate the company's progress in the semiconductor market and develop scalable opportunities in life sciences. The investment will also bring Ampersand partner David Patteson to Syft’s board to support commercial growth and scale-up.

Ampersand Capital Partners Invests in BioEcho Life Sciences

March 1, 2022

Biotechnology

Ampersand Capital Partners made a minority growth equity investment in Cologne-based BioEcho Life Sciences to support the company's global expansion, new product launches, and expansion of its direct salesforce. As part of the transaction Ampersand appointed Frank Witney and Arya Mehrabanzad to BioEcho's board; financial terms were not disclosed.

Ampersand Capital Partners Makes Growth Investment in GeneWerk GmbH

September 21, 2020

Biotechnology

Ampersand Capital Partners has made a majority growth equity investment in GeneWerk GmbH to expand the company's cell and gene therapy testing capabilities and support U.S. and European market expansion. GeneWerk, a Heidelberg-based clinical and preclinical testing laboratory known for vector integration site analysis and bioinformatics services, will use the capital to scale capabilities and meet rising demand for cell and gene therapy testing.

Ampersand Capital Partners Majority Recapitalizes N2 Biomedical

June 18, 2019

Medical Devices

Ampersand Capital Partners completed a majority recapitalization of N2 Biomedical, a Bedford, Massachusetts-based provider of coating and surface treatment solutions for the medical device industry. The transaction positions N2 to accelerate growth and broaden its service offering; Ampersand also supported the appointment of Randall Sword as President and CEO while co-founders remain shareholders.